NimbleGen gains patents covering manufacture, use, and sales of nucleic acid microarrays.
NimbleGen Systems obtained a nonexclusive, worldwide license to a number of Affymetrix patents covering the manufacture, use, and sales of nucleic acid microarrays and related products and services in the research field.
“This licensing agreement with NimbleGen follows from a commercial relationship and enables both companies to better serve customers within the growing microarray market,” says Alan Sherr, vp and chief counsel for licensing at Affymetrix.